Back to GetFilings.com



Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

FORM 10-Q

 


 

(MARK ONE)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2004

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE TRANSITION PERIOD FROM              TO              .

 

COMMISSION FILE NUMBER: 000-30369

 


 

VIROLOGIC, INC.

(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

 


 

DELAWARE   94-3234479
(STATE OR OTHER JURISDICTION OF
INCORPORATION OR ORGANIZATION)
 

(IRS EMPLOYER

IDENTIFICATION NO.)

 

345 OYSTER POINT BLVD

SOUTH SAN FRANCISCO, CA 94080

(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

 

TELEPHONE NUMBER (650) 635-1100

(REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE)

 


 

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

 

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Act).    Yes  ¨    No  x

 

As of August 12, 2004 there were 53,671,790 shares of the registrant’s common stock outstanding.

 



Table of Contents

VIROLOGIC, INC.

 

INDEX

 

     PAGE
NO.


PART I. FINANCIAL INFORMATION

    

Item 1. Financial Statements

    

             Condensed Balance Sheets as of June 30, 2004 and December 31, 2003

   3

             Condensed Statements of Operations for the three and six months ended June 30, 2004 and 2003

   4

             Condensed Statements of Cash Flows for the six months ended June 30, 2004 and 2003

   5

             Notes to Condensed Financial Statements

   6

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

   11

Item 3. Quantitative and Qualitative Disclosures About Market Risk

   31

Item 4. Controls and Procedures

   31

PART II. OTHER INFORMATION

    

Item 1. Legal Proceedings

   32

Item 2. Changes in Securities, Use of Proceeds and Issuer Purchases of Equity Securities

   32

Item 3. Defaults Upon Senior Securities

   32

Item 4. Submission of Matters to a Vote of Security Holders

   32

Item 5. Other Information

   32

Item 6. Exhibits and Reports on Form 8-K

   32

Signatures

   33

 

2


Table of Contents

VIROLOGIC, INC.

CONDENSED BALANCE SHEETS

(In thousands, except share data)

 

    

June 30,

2004


   

December 31,

2003


 
     (Unaudited)     (Note 1)  

ASSETS

                

Current assets:

                

Cash and cash equivalents

   $ 9,216     $ 8,893  

Short-term investments

     250       537  

Accounts receivable, net of allowance for doubtful accounts of $598 and $643 at June 30, 2004 and December 31, 2003, respectively

     5,858       6,165  

Prepaid expenses

     599       700  

Inventory

     1,014       1,378  

Restricted cash

     626       426  

Other current assets

     248       267  
    


 


Total current assets

     17,811       18,366  

Property and equipment, net

     7,409       8,445  

Restricted cash

     50       350  

Transaction costs related to pending merger

     1,686       —    

Other assets

     1,464       1,217  
    


 


Total assets

   $ 28,420     $ 28,378  
    


 


LIABILITIES AND STOCKHOLDERS’ EQUITY

                

Current liabilities:

                

Accounts payable

   $ 2,912     $ 1,556  

Accrued compensation

     999       862  

Accrued liabilities

     2,818       2,108  

Deferred revenue

     715       268  

Current portion of capital lease obligations

     205       401  

Current portion of loans payable

     —         133  
    


 


Total current liabilities

     7,649       5,328  

Long-term portion of capital lease obligations

     43       87  

Other long-term liabilities

     379       382  

Redeemable convertible preferred stock, $0.001 par value, 274 shares authorized, designated by series, issued and outstanding at June 30, 2004 and December 31, 2003; aggregate liquidation preference of $2,856 at June 30, 2004

     1,994       1,994  

Commitments

                

Stockholders’ equity:

                

Preferred stock, $0.001 par value, 4,999,726 shares authorized, designated by series, none issued and outstanding at June 30, 2004 and December 31, 2003

     —         —    

Common stock, $0.001 par value, 100,000,000 shares authorized; 53,636,768 and 52,608,382 shares issued and outstanding at June 30, 2004 and December 31, 2003, respectively

     54       53  

Additional paid-in capital

     127,192       126,805  

Accumulated other comprehensive income

     —         1  

Accumulated deficit

     (108,891 )     (106,272 )
    


 


Total stockholders’ equity

     18,355       20,587  
    


 


Total liabilities and stockholders’ equity

   $ 28,420     $ 28,378  
    


 


 

See accompanying notes to Condensed Financial Statements.

 

3


Table of Contents

VIROLOGIC, INC.

CONDENSED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited)

 

     Three Months Ended
June 30,


    Six Months Ended
June 30,


 
     2004

    2003

    2004

    2003

 

Revenue:

                                

Product revenue

   $ 8,734     $ 7,786     $ 17,374     $ 14,337  

Contract revenue

     493       167       875       584  
    


 


 


 


Total revenue

     9,227       7,953       18,249       14,921  

Operating costs and expenses:

                                

Cost of product revenue

     4,475       4,268       8,891       8,087  

Research and development

     1,600       1,089       2,993       2,435  

Sales and marketing

     2,784       2,469       4,742       4,311  

General and administrative

     1,750       2,375       3,830       4,841  

Lease termination charge

     —         —         433       —    
    


 


 


 


Total costs and expenses

     10,609       10,201       20,889       19,674  
    


 


 


 


Operating loss

     (1,382 )     (2,248 )     (2,640 )     (4,753 )

Interest income

     19       26       40       63  

Interest expense

     (8 )     (36 )     (19 )     (88 )

Other income

     —         52       —         104  
    


 


 


 


Net loss

     (1,371 )     (2,206 )     (2,619 )     (4,674 )

Deemed dividend to preferred stockholders

     —         —         —         (2,155 )

Preferred stock dividend

     (77 )     (506 )     (145 )     (973 )
    


 


 


 


Loss applicable to common stockholders

   $ (1,448 )   $ (2,712 )   $ (2,764 )   $ (7,802 )
    


 


 


 


Basic and diluted loss per common share

   $ (0.03 )   $ (0.09 )   $ (0.05 )   $ (0.27 )
    


 


 


 


Weighted-average shares used in computing basic and diluted loss per common share

     53,494       29,643       53,376       29,001  
    


 


 


 


 

See accompanying notes to Condensed Financial Statements.

 

4


Table of Contents

VIROLOGIC, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 

     Six Months Ended
June 30,


 
     2004

    2003

 

OPERATING ACTIVITIES

                

Net loss

   $ (2,619 )   $ (4,674 )

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

                

Depreciation and amortization

     1,375       1,708  

Loss on disposal of fixed assets related to lease termination

     108       —    

Stock-based compensation

     36       149  

Amortization of deferred gain on lease assignment

     —         (104 )

Changes in assets and liabilities

                

Accounts receivable

     307       534  

Prepaid expenses

     101       (168 )

Inventory

     364       212  

Other current assets

     19       17  

Accounts payable

     332       732  

Accrued compensation

     137       (19 )

Accrued liabilities

     418       (343 )

Deferred revenue

     447       (11 )

Long-term deferred rent

     (3 )     (20 )
    


 


Net cash provided by (used in) operating activities

     1,022       (1,987 )

INVESTING ACTIVITIES

                

Purchases of short-term investments

     (4 )     (4,569 )

Maturities and sales of short-term investments

     290       4,565  

Capital expenditures

     (447 )     (69 )

Restricted cash

     100       (349 )

Transaction costs related to pending merger

     (389 )     —    

Other assets

     (247 )     (184 )
    


 


Net cash used in investing activities

     (697 )     (606 )

FINANCING ACTIVITIES

                

Principal payments on loans payable

     (133 )     (416 )

Payments on capital lease obligations

     (240 )     (501 )

Net proceeds from issuance of common stock

     371       1,111  

Expenses relating to issuance of preferred stock

     —         (397 )
    


 


Net cash used in financing activities

     (2 )     (203 )
    


 


Net increase (decrease) in cash and cash equivalents

     323       (2,796 )

Cash and cash equivalents at beginning of period

     8,893       10,559  
    


 


Cash and cash equivalents at end of period

   $ 9,216     $ 7,763  
    


 


 

See accompanying notes to Condensed Financial Statements.

 

5


Table of Contents

VIROLOGIC, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

June 30, 2004

(Unaudited)

 

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by US generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting only of adjustments of a normal recurring nature) considered necessary for a fair presentation have been included. Operating results for the six-month period ended June 30, 2004 are not necessarily indicative of the results that may be expected for the year ending December 31, 2004 or any other future periods. The condensed balance sheet as of December 31, 2003 has been derived from the audited financial statements as of that date but does not include all of the information and footnotes required by US generally accepted accounting principles for complete financial statements. For further information, refer to the audited financial statements and notes thereto included in our Annual Report to Stockholders on Form 10-K for the year ended December 31, 2003.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial stat